Early Management Strategies of Acute Heart Failure for Patients With NSTEMI
Status:
Enrolling by invitation
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
There are always poor outcomes in patients with acute myocardial infarction(AMI) combined
with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute
heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and
Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when
patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to
use levosimendan may reduces the risk of heart failure and improve the outcome.